RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of “Hold” by Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has been assigned a consensus rating of “Hold” from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $24.67.

Several equities research analysts recently weighed in on RAPT shares. Barclays downgraded RAPT Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $13.00 to $4.00 in a report on Friday, May 10th. SVB Leerink downgraded RAPT Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $42.00 to $10.00 in a report on Wednesday, February 21st. Guggenheim downgraded RAPT Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 10th. UBS Group downgraded RAPT Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $61.00 to $10.00 in a report on Thursday, February 22nd. Finally, Cantor Fitzgerald downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, February 20th.

RAPT Therapeutics Price Performance

Shares of NASDAQ RAPT opened at $4.49 on Friday. The stock has a fifty day moving average price of $7.44 and a 200 day moving average price of $14.61. RAPT Therapeutics has a 1-year low of $3.95 and a 1-year high of $27.35. The company has a market cap of $156.53 million, a PE ratio of -1.46 and a beta of 0.52.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.05. Analysts anticipate that RAPT Therapeutics will post -2.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. FMR LLC increased its position in shares of RAPT Therapeutics by 7.4% in the third quarter. FMR LLC now owns 4,499,293 shares of the company’s stock valued at $74,778,000 after buying an additional 308,804 shares in the last quarter. Vanguard Group Inc. increased its position in RAPT Therapeutics by 21.2% during the 1st quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock worth $22,386,000 after purchasing an additional 436,629 shares in the last quarter. Perceptive Advisors LLC increased its position in RAPT Therapeutics by 11.4% during the 4th quarter. Perceptive Advisors LLC now owns 2,139,950 shares of the company’s stock worth $53,178,000 after purchasing an additional 219,292 shares in the last quarter. Kingdon Capital Management L.L.C. increased its position in RAPT Therapeutics by 55.3% during the 1st quarter. Kingdon Capital Management L.L.C. now owns 1,500,000 shares of the company’s stock worth $13,470,000 after purchasing an additional 534,172 shares in the last quarter. Finally, Braidwell LP increased its position in RAPT Therapeutics by 10.0% during the 3rd quarter. Braidwell LP now owns 1,082,512 shares of the company’s stock worth $17,991,000 after purchasing an additional 98,112 shares in the last quarter. Hedge funds and other institutional investors own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.